ABCL vs. ELVN, PRTA, VRNA, COLL, MIRM, IRWD, BLTE, MNKD, INVA, and SAVA
Should you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Enliven Therapeutics (ELVN), Prothena (PRTA), Verona Pharma (VRNA), Collegium Pharmaceutical (COLL), Mirum Pharmaceuticals (MIRM), Ironwood Pharmaceuticals (IRWD), Belite Bio (BLTE), MannKind (MNKD), Innoviva (INVA), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical preparations" industry.
Enliven Therapeutics (NASDAQ:ELVN) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 45.8% of Enliven Therapeutics shares are held by company insiders. Comparatively, 32.5% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, AbCellera Biologics had 3 more articles in the media than Enliven Therapeutics. MarketBeat recorded 14 mentions for AbCellera Biologics and 11 mentions for Enliven Therapeutics. AbCellera Biologics' average media sentiment score of 0.72 beat Enliven Therapeutics' score of 0.23 indicating that Enliven Therapeutics is being referred to more favorably in the media.
Enliven Therapeutics has a net margin of 0.00% compared to Enliven Therapeutics' net margin of -410.47%. Enliven Therapeutics' return on equity of -12.61% beat AbCellera Biologics' return on equity.
Enliven Therapeutics has higher earnings, but lower revenue than AbCellera Biologics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
Enliven Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.
AbCellera Biologics received 47 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 77.27% of users gave AbCellera Biologics an outperform vote.
Enliven Therapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 47.57%. AbCellera Biologics has a consensus target price of $16.17, suggesting a potential upside of 344.14%. Given Enliven Therapeutics' higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Enliven Therapeutics.
Summary
AbCellera Biologics beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.
Get AbCellera Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AbCellera Biologics Competitors List
Related Companies and Tools
